Through this commitment, the government of the United Arab Emirates, Medicines for Malaria Venture, and the Global Medical Forum Foundation will establish a new biomedical center that will draw on the strengths and capabilities of community, regional, and national partners to address the growing challenges of malaria. The center seeks first to accelerate the discovery and development of novel anti-malarial agents, and then to distribute them to regions where malaria is endemic. The center's ideal positioning, in terms of regional accessibility, financial support and human resources, will help fulfill this ambition.
With faculties for biomedical R&D, drug production, education and training, the Center will seek to implement the following goals:
1. Drug Discovery: Developing a sustainable pipeline capable of submitting one completely novel compound for clinical development. Such compounds will be manufactured for clinical investigation and therapeutic usage.
2. Drug Distribution: Establishing the center as a major distribution hub for malaria medicines and other preventative treatments. Regimens will reach countries in which malaria is endemic and the UAE holds influence.
3. Professional Medical Training: Establishing an educational program for medical and paramedical staff from the surrounding region. Staff will receive training in malaria prevention and treatment.
4. Positive Policy Change: Creating an active policy institute within the center where leaders from the region can receive professional training on the importance of malaria R&D, treatment and prevention. The policy platform will sustain UAE's role in helping to alleviate the malaria endemic.
Phase I of the project will focus on financing; Phase II will produce a feasibility study and full business plan; Phase III will comprise implementation and construction of the project as a part of the Abu Dhabi Bio City, as per the feasibility study and business plan.
The center will draw on the strengths and capabilities of community, regional, and national partners to address the growing challenges of malaria.
Abu Dhabi Bio City is a new mixed-use, $180 million biomedical cluster being developed in Abu Dhabi by a consortium whose partners include the Global Medical Forum Foundation (GMF) of Zurich, Switzerland, Bio City Development Corporation (BCDco) of Hong Kong, Abu Dhabi Commercial Bank of Abu Dhabi, and Macquarie Bank of Australia. Its development coincides with the founding of an additional $150 million biomedical research investment fund by HBM Partners of Zurich Switzerland and Abu Dhabi Commercial Bank, which will support early and mid-stage companies within the cluster.
ADBC therefore represents the $330 million commitment to create a center of excellence for research and development in the life sciences in the Middle East, containing major R&D facilities for pharmaceutical, biotechnology and medical technology companies.